And if migraines happen regularly, they can seriously disrupt your life. The good news? There are simple, proactive steps you ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

While a headache is a symptom, a migraine is a neurological condition that affects millions worldwide and can cause significant disability in those who suffer from it. It's estimated that up to 15 ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement saying his office and 37 other states, including Puerto Rico, had settled ...

FDA Approves Symbravo for Acute Treatment of Migraine in Adults By Lori Solomon HealthDay Reporter WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...

Without a proper diagnosis, medications that can help reduce migraine may be delayed. Unfortunately, our study found racial and ethnic disparities in the diagnosis, testing and treatment of migraine." ...

SG Americas Securities LLC cut its position in Biohaven Ltd. (NYSE ... that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate ...